A5045910613- CAR-T cell therapy research
- Immune Cell Function and Interaction
- CRISPR and Genetic Engineering
- Pluripotent Stem Cells Research
- T-cell and B-cell Immunology
- Transgenic Plants and Applications
- RNA Interference and Gene Delivery
- Animal Genetics and Reproduction
- Immune Response and Inflammation
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- Nanowire Synthesis and Applications
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
- Immunotherapy and Immune Responses
National University of Singapore
2017-2023
Centre for Human Genetics
2017
University of Oxford
2017
Fudan University
2014
State Key Laboratory of Genetic Engineering
2014
Promising progress has been made in adoptive transfer of allogeneic natural killer (NK) cells to treat relapsed or refractory acute myeloid leukemia (AML). In this regard, chimeric antigen receptor (CAR)-modification NK is considered as a compelling approach augment the specificity and cytotoxicity against AML. Using non-viral piggyBac transposon technology human peripheral blood-derived primary cells, we generated CAR-NK target NKG2D ligands demonstrated their vitro activity lysing cancer...
Abstract Background Redirection of natural killer (NK) cells with chimeric antigen receptors (CAR) is attractive in developing off-the-shelf CAR therapeutics for cancer treatment. However, the site-specific integration a gene into NK remains challenging. Methods In present study, we genetically modified human induced pluripotent stem (iPSCs) zinc finger nuclease (ZFN) technology to introduce cDNA encoding an anti-EpCAM adeno-associated virus site 1, “safe harbour” transgene insertion genome,...
Genome manipulation in the mouse via microinjection of CRISPR/Cas9 site-specific nucleases has allowed production time for genetically modified models to be significantly reduced. Successful genome already been reported using Cas9 supplied by a DNA construct, vitro transcribed mRNA and recombinant protein. Recently use transgenic strains mice overexpressing shown facilitate mutagenesis maternal supply zygotes this route may provide an alternative exogenous supply. We have investigated...
HIV latency is the foremost barrier to clearing infection from patients. Reactivation of latent HIV-1 represents a promising strategy deplete these viral reservoirs. Here, we report novel approach reactivate provirus using artificially designed transcription activator-like effector (TALE) fusion proteins containing DNA-binding domain specifically targeting promoter and herpes simplex virus-based transcriptional activator VP64 domain. We engineered four TALE genes (TALE1-4) encoding proteins,...
Mesenchymal stromal cells (MSCs) are viewed as immune-privileged and have been broadly applied in allogeneic adoptive cell transfer for regenerative medicine or immune-suppressing purpose. However, the surface expression of human leukocyte antigen (HLA) class I molecules on MSCs could still possibly induce rejection from recipients. Here, we disrupted β2 microglobulin ( B2M) gene peripheral blood mononuclear cell-derived induced pluripotent stem (iPSCs) with two clustered regulatory...
Aim: To investigate whether anti-CD123 chimeric antigen receptor (CAR)-expressing Vγ9Vδ2 T cells could be an alternative for acute myeloid leukemia (AML) treatment. Materials & methods:Ex vivo expanded were electroporated with CAR-encoding mRNA. The effector function and specificity of the modified examined by in vitro cytotoxicity, degranulation cytokine release level. was analyzed using xenograft KG1-luc model NOD-SCID-γc-/- mice. Results: exhibited significantly improved activities...
Aim: The human K562 leukemia cell line as a scaffold of artificial antigen presenting cells (aAPCs) for ex vivo lymphocyte expansion does not usually express major histocompatibility complex (MHC) molecules. However, when stimulated by supernatants from T cultures, upregulate β-2 microglobulin (B2M) and MHC class I expression, which would induce allo-specific cells. Methods: We disrupted the B2M locus in CRISPR/Cas9 achieved I-negative Results: further generated K562-based aAPC zinc-finger...
Abstract Peritoneal carcinomatosis (PC) is widely shown in end-stage neoplastic disease, especially recurrent colorectal cancer, and has become a significant threat to the overall survival of patients. Since NKG2D ligands are commonly up-regulated on cell surface carcinomas but rarely present most healthy tissues, they can be ideal targets treatment ligand-overexpressing PC. In this study, we developed chimeric antigen receptor (CAR)-T therapy approach by arming human T lymphocytes with mRNA...